Venture-backed Xenon Pharmaceuticals to raise $36 mln in IPO
Xenon Pharmaceuticals Inc has priced its previously announced initial public offering (IPO). The Canadian clinical-stage biopharmaceutical company said it intends to raise $36 million in gross proceeds based on an offering of 4 million common shares at a price of $9 per share. The offering includes an additional purchase option of 600,000 shares. Xenon will begin trading this week on Nasdaq under the symbol "XENE." Based in Burnaby, British Columbia, the company's investors include Fidelity Investments, Five Corners Capital, InterWest Partners, Invesco Private Capital, LipoteRx, MX Associates and RBC Capital Partners.
6 November 2014•2 mins read
